Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo

@article{Lin2006FascaplysinAS,
  title={Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo},
  author={Jing Lin and Xiao-jun Yan and Haimin Chen},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2006},
  volume={59},
  pages={439-445}
}
This study was to evaluate the correlation of two important strategies, namely, cell cycle proliferation arrest and anti-angiogenesis. We chose fascaplysin, a marine natural product with selective CDK4 selective inhibition activity, to study its potential anti-angiogenesis effects in vivo and in vitro. Chorioallantoic membrane (CAM) assay was initially used as an in vivo approach to evaluate anti-angiogenic activity of fascaplysin. In addition, human umbilical vein endothelial cell (HUVEC) line… CONTINUE READING